Orchid Pharma Limited

BSE:524372 Stock Report

Market Cap: ₹90.8b

Orchid Pharma Past Earnings Performance

Past criteria checks 2/6

Orchid Pharma has been growing earnings at an average annual rate of 72%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 21.4% per year. Orchid Pharma's return on equity is 9.8%, and it has net margins of 13.2%.

Key information

72.0%

Earnings growth rate

110.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate21.4%
Return on equity9.8%
Net Margin13.2%
Next Earnings Update14 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Orchid Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524372 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,0481,1958130
30 Jun 248,8091,1217880
31 Mar 248,1949227300
31 Dec 238,1221,2467030
30 Sep 237,5131,0276780
30 Jun 237,1787756800
31 Mar 236,6595316640
31 Dec 226,341-1756460
30 Sep 226,357-3566540
30 Jun 225,982-4716430
31 Mar 225,596-6046490
31 Dec 215,010-5926060
30 Sep 214,424-9346230
30 Jun 214,232-1,0096550
31 Mar 214,501-9526860
31 Dec 204,420-1,3078820
30 Sep 204,687-1,1368000
30 Jun 204,918-1,1538140
31 Mar 204,838-6978630
31 Mar 196,0006949450
31 Mar 186,830-3,5289840
31 Mar 177,965-4,9549210
31 Mar 168,734-2,7919880
31 Mar 1511,644-1,3111,3970

Quality Earnings: 524372 has high quality earnings.

Growing Profit Margin: 524372's current net profit margins (13.2%) are lower than last year (13.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524372 has become profitable over the past 5 years, growing earnings by 72% per year.

Accelerating Growth: 524372's earnings growth over the past year (16.4%) is below its 5-year average (72% per year).

Earnings vs Industry: 524372 earnings growth over the past year (16.4%) did not outperform the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 524372's Return on Equity (9.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:39
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orchid Pharma Limited is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAngel Broking Private Limited
Sudarshan PadmanabhanBatlivala & Karani Securities India Pvt. Ltd.
Pauline LauBofA Global Research